Megakaryocyte growth and development factor (MGDF): An Mpl ligand and cytokine that regulates thrombopoiesis

Cytokines, Cellular and Molecular Therapy

Volumn 6, Issue 1, 2000, Pages 47-56

  Kirley Neumann, T A ^a   Foote, M ^a  

^a AMGEN INC   (United States)

Author keywords

MGDF; Platelet function; Recombinant protein; Thrombopoiesis

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT PROTEIN;

ANTIBODY PRODUCTION; HEMATOPOIETIC SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REGULATORY MECHANISM; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 0033849494     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: 10.1080/13684730050515912     Document Type: Review

References (80)

1. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl
2. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor
3. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia
4. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-mpl, produces functional human platelets in vitro
5. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice
6. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates
7. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer
8. Randomized, blinded, placebo-controlled phase 1 trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer
9. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer
10. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
11. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
12. Cyclic thrombocytopenia with platelet auto-antibodies: Response to PEG-rHuMegakaryocyte growth and development factor
13. Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma
14. Thrombopoietin: Its biology, purification, and characterization
15. Two-factor requirement for murine megakaryocyte colony formation
16. Demonstration and some properties of human thrombopoietin in thrombocythemic sera
17. Stimulation of platelet production by serum of platelet depleted rats
18. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors
19. Molecular cloning and characterization of mpl, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily
20. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis
21. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production
22. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene
23. Purification and characterization of thrombopoietin
24. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura
25. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit
26. Regulation of platelet production
27. The uses and properties of PEG-linked proteins
28. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice
29. Pharmacokinetics (PK) of PEG-rHuMGDF (M) and platelet response in healthy rhesus monkeys (RhMk)
30. Thrombopoietin signal transduction: Studies from cell lines and primary cells
31. The thrombopoietin receptor, Mpl, and signal transduction
32. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelet in vitro
33. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets
34. The thrombopoietin receptor c-mpl activates JAK2 and TYK2 tyrosine kinases
35. In vivo stimulation of platelet production in a primate model using IL-1 and IL-3
36. In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates
37. Recombinant human granulocyte-macrophage colony stimulating factor promotes megakaryocyte maturation in nonhuman primates
38. Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates
39. Stimulation megakaryocytopoiesis in mice by human recombinant interleukin-6
40. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice
41. Effects of injected leukemia inhibitory, factor (LIF) on hemopoietic and other tissues in mice
42. Thrombopoietic properties of oncostatin M
43. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice
44. Genetic manipulation of Mpl ligand and thrombopoietin in vivo
45. Preliminary report: Effects of interleukin-1 on platelet counts
46. Phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer
47. Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation
48. A phase I clinical trial of recombinant human interleukin-6 (rHIL-6) in solid tumors
49. Thrombopoietic effects of interleukin-6 in long-term administration in mice
50. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled randomized phase Ib study
51. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy
52. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy
53. Interleukin-11 enhances human megakaryocytopoiesis in vitro
54. Neumega® (oprelvekin; rhIl-11) prevents severe chemotherapy-induced thrombocytopenia in abbreviated phase 3 study
55. Human recombinant granulocyte-macrophage colony-stimulating factor: A multilineage hematopoietin
56. Hematologic effects of stem cell factor in vivo and in vitro
57. An overview of thrombopoietin: With a historical perspective
58. The appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit
59. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis
60. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin
61. Recombinant human interleukin 11 stimulates multilineage hematopoietic recovery in mice after myelosuppressive regimen of sublethal irradiation and carboplatin
62. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine model of myelosuppression
63. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice
64. Chronic exposure to retroviral vector encoded MGDF (Mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice
65. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia
66. Effect of recombinant human interleuki-6 (rhLL-6) and rhLL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model
67. Recombinant thrombopoietin stimulates rapid platelet recovery in thrombocytopenic mice
68. Prevention of thrombocytopenia and neutropenia in a non-human primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor
69. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates
70. Recombinant human megakaryocyte growth and development factor (MGDF) moderately enhances ex vivo platelet aggregation by a receptor dependent mechanism
71. Regulation of platelet activation in vitro by the c-Mpl ligand thrombopoietin
72. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation
73. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
74. Serum levels of thrombopoietin in health and disease
75. Diagnosis, clinical course and management of idiopathic thrombocytopenia purpura
76. Prognostic value of c-mpl expression in myelodysplastic syndromes
77. The mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets
78. Effect of a single dose of pegylated human recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet counts: Implication for platelet apheresis
79. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases platelet (plt) count (ct) and apheresis yields of normal plt donors: Initial results
80. Cell therapy in peripheral stem cell transplantation: The development of cell isolation techniques